Latest Als Research News

Page 1 of 1

FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Platform Trial Entry

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Ada Torres

11 Dec 2025

Top